Rebamipide
- ₹5200 - ₹29541.43
- Product name: Rebamipide
- CAS: 90098-04-7
- MF: C19H15ClN2O4
- MW: 370.79
- EINECS:1308068-626-2
- MDL Number:MFCD00866895
- Synonyms:(+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoica ;(+-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionicacid ;Mucosta;Proamipide;2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo- (+-)-4-quinolinepropanoic acid;2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid;2-(4-CHLOROBENZAMIDO)-3-(2-OXO-1,2-DIHYDROQUINOLIN-4-YL)PROPANOIC ACID;OPC-12759, Mucosta, α-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic Acid
5 prices
Selected condition:
Brand
- TCI Chemicals (India)
- Sigma-Aldrich(India)
Package
- 5MG
- 25MG
- 1G
- 5G
- 25G
- ManufacturerTCI Chemicals (India)
- Product numberR0085
- Product descriptionRebamipide
- Packaging1G
- Price₹5200
- Updated2022-05-26
- Buy
- ManufacturerTCI Chemicals (India)
- Product numberR0085
- Product descriptionRebamipide
- Packaging5G
- Price₹5900
- Updated2022-05-26
- Buy
- ManufacturerTCI Chemicals (India)
- Product numberR0085
- Product descriptionRebamipide
- Packaging25G
- Price₹20000
- Updated2022-05-26
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberR5655
- Product descriptionRebamipide hydrate ≥98% (HPLC), powder
- Packaging5MG
- Price₹7404.3
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberR5655
- Product descriptionRebamipide hydrate ≥98% (HPLC), powder
- Packaging25MG
- Price₹29541.43
- Updated2022-06-14
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
TCI Chemicals (India) | R0085 | Rebamipide | 1G | ₹5200 | 2022-05-26 | Buy |
TCI Chemicals (India) | R0085 | Rebamipide | 5G | ₹5900 | 2022-05-26 | Buy |
TCI Chemicals (India) | R0085 | Rebamipide | 25G | ₹20000 | 2022-05-26 | Buy |
Sigma-Aldrich(India) | R5655 | Rebamipide hydrate ≥98% (HPLC), powder | 5MG | ₹7404.3 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | R5655 | Rebamipide hydrate ≥98% (HPLC), powder | 25MG | ₹29541.43 | 2022-06-14 | Buy |
Properties
Melting point :288-290°C dec.
Boiling point :695.0±55.0 °C(Predicted)
Density :1.394±0.06 g/cm3(Predicted)
storage temp. :Sealed in dry,Room Temperature
solubility :DMSO: >5mg/mL
pka :3.38±0.10(Predicted)
form :powder
color :white
Merck :14,8124
InChIKey :ALLWOAVDORUJLA-UHFFFAOYSA-N
CAS DataBase Reference :90098-04-7(CAS DataBase Reference)
Boiling point :695.0±55.0 °C(Predicted)
Density :1.394±0.06 g/cm3(Predicted)
storage temp. :Sealed in dry,Room Temperature
solubility :DMSO: >5mg/mL
pka :3.38±0.10(Predicted)
form :powder
color :white
Merck :14,8124
InChIKey :ALLWOAVDORUJLA-UHFFFAOYSA-N
CAS DataBase Reference :90098-04-7(CAS DataBase Reference)
Safety Information
Symbol(GHS): | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | ||||||||||||||
Hazard statements: |
|
||||||||||||||
Precautionary statements: |
|
Description
Rebamipide is a quinolinone derivative that stimulates endogenous PGE2 generation in gastric mucosa, enhancing gastric mucosal defense in a COX-2-dependent manner.Rebamipide has been shown to inhibit the production of reactive oxygen species and to decrease cytokine release induced by H. pylori infection.
A daily oral dose of 100 mg/kg was found to be protective against the development of pyloric channel ulcers in Mongolian gerbils infected with H. pylori.
In addition to the stomach, rebamipide can also enhance secretion of mucin covering the conjunctiva and cornea, which is important for tear film adhesion.
Rebamipide, a gastroprotective drug, was developed in Japan and was proven to be superior to cetraxate, the former most prescribed drug of the same category, in 1989 in the treatment for gastric ulcers. The initially discovered basic mechanisms of action of rebamipide included its action as a prostaglandin inducer and oxygen free-radical scavenger. In the last 5 years, several basic and clinical studies have been performed for functional dyspepsia, chronic gastritis, NSAID-induced gastrointestinal injuries, gastric ulcer following eradication therapy for Helicobacter pylori, gastric ulcer after endoscopic surgery and ulcerative colitis. In addition, several molecules have been identified as therapeutic targets of rebamipide to explain its pleiotropic pharmacological actions.
More related product prices
36556-06-6 Propionic acid Clioquinol ACETIC ACID Folic acid 2,6-Dimethyl-7-octen-2-ol Omeprazole Rebeprazole sodium Esomeprazole DL-3-(1,2-Dihydro-2-oxo-quinoline-4-yl)alanine hydrochloride 4-Chlorobenzamide 2-Amino-3-(1,2-dihydro-2-oxoquinoline-4-yl)propanoic acid RebamipideRelated product price
- 36556-06-6
₹5964.58-21552.58 - Propionic acid
₹480-43470 - Clioquinol
₹2900-27571.28